Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
This article was originally published in The Pink Sheet Daily
Pfizer is willing to make a “bold” M&A move, including one that will improve the company’s tax situation, CEO Ian Read told Q3 earnings call, despite the US government’s initiatives to curb tax inversion deals.
You may also be interested in...
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.